These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Effects of long-term treatment with prostacyclin on plasma adrenomedullin in patients with primary pulmonary hypertension]. Nakayama T; Ishikita T; Matsuura H; Saji T J Cardiol; 2001 Nov; 38(5):263-71. PubMed ID: 11729726 [TBL] [Abstract][Full Text] [Related]
5. Short and long term anti-inflammatory effects of bosentan therapy in patients with pulmonary arterial hypertension: relation to clinical and hemodynamic responses. Karavolias GK; Georgiadou P; Gkouziouta A; Kariofillis P; Karabela G; Tsiapras D; Sbarouni E; Chaidaroglou A; Degiannis D; Adamopoulos S; Voudris V Expert Opin Ther Targets; 2010 Dec; 14(12):1283-9. PubMed ID: 20958219 [TBL] [Abstract][Full Text] [Related]
6. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. D'Alto M; Romeo E; Argiento P; Sarubbi B; Santoro G; Grimaldi N; Correra A; Scognamiglio G; Russo MG; Calabrò R Int J Cardiol; 2012 Mar; 155(3):378-82. PubMed ID: 21081251 [TBL] [Abstract][Full Text] [Related]
7. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Provencher S; Sitbon O; Humbert M; Cabrol S; Jaïs X; Simonneau G Eur Heart J; 2006 Mar; 27(5):589-95. PubMed ID: 16431875 [TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974 [TBL] [Abstract][Full Text] [Related]
9. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. McLaughlin VV Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005 [TBL] [Abstract][Full Text] [Related]
10. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Wilkins MR; Paul GA; Strange JW; Tunariu N; Gin-Sing W; Banya WA; Westwood MA; Stefanidis A; Ng LL; Pennell DJ; Mohiaddin RH; Nihoyannopoulos P; Gibbs JS Am J Respir Crit Care Med; 2005 Jun; 171(11):1292-7. PubMed ID: 15750042 [TBL] [Abstract][Full Text] [Related]
11. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ; J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129 [TBL] [Abstract][Full Text] [Related]
12. Response to bosentan in children with pulmonary hypertension. Maiya S; Hislop AA; Flynn Y; Haworth SG Heart; 2006 May; 92(5):664-70. PubMed ID: 16216850 [TBL] [Abstract][Full Text] [Related]
13. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. Barst RJ; Oudiz RJ; Beardsworth A; Brundage BH; Simonneau G; Ghofrani HA; Sundin DP; Galiè N; J Heart Lung Transplant; 2011 Jun; 30(6):632-43. PubMed ID: 21256048 [TBL] [Abstract][Full Text] [Related]
14. Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue diseases. Cella G; Vianello F; Cozzi F; Marotta H; Tona F; Saggiorato G; Iqbal O; Fareed J J Rheumatol; 2009 Apr; 36(4):760-7. PubMed ID: 19208592 [TBL] [Abstract][Full Text] [Related]
15. Long-term outcome and effects of oral bosentan therapy in Taiwanese patients with advanced idiopathic pulmonary arterial hypertension. Hsu HH; Chen JS; Chen RJ; Ko WJ; Kuo SW; Wu ET; Wu MH; Wang JK; Lee YC Respir Med; 2007 Jul; 101(7):1556-62. PubMed ID: 17223329 [TBL] [Abstract][Full Text] [Related]
16. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. Simonneau G; Galiè N; Jansa P; Meyer GM; Al-Hiti H; Kusic-Pajic A; Lemarié JC; Hoeper MM; Rubin LJ Int J Cardiol; 2014 Mar; 172(2):332-9. PubMed ID: 24525158 [TBL] [Abstract][Full Text] [Related]
17. Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension. Souza R; Jardim C; Martins B; Cortopassi F; Yaksic M; Rabelo R; Bogossian H Curr Med Res Opin; 2005 Jun; 21(6):907-11. PubMed ID: 15969891 [TBL] [Abstract][Full Text] [Related]
18. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Galiè N; Rubin Lj; Hoeper M; Jansa P; Al-Hiti H; Meyer G; Chiossi E; Kusic-Pajic A; Simonneau G Lancet; 2008 Jun; 371(9630):2093-100. PubMed ID: 18572079 [TBL] [Abstract][Full Text] [Related]
19. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease. Diller GP; Dimopoulos K; Kaya MG; Harries C; Uebing A; Li W; Koltsida E; Gibbs JS; Gatzoulis MA Heart; 2007 Aug; 93(8):974-6. PubMed ID: 17639112 [TBL] [Abstract][Full Text] [Related]
20. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease. Kotlyar E; Sy R; Keogh AM; Kermeen F; Macdonald PS; Hayward CS; McNeil KD; Celermajer DS Cardiol Young; 2006 Jun; 16(3):268-74. PubMed ID: 16725066 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]